ReutersFrance's Sanofi plans to invest at least $20 billion in United States
- Bias Rating
-6% Center
- Reliability
30% ReliableAverage
- Policy Leaning
-10% Center
- Politician Portrayal
2% Positive
Continue For Free
Create your free account to see the in-depth bias analytics and more.
Continue
Continue
By creating an account, you agree to our Terms and Privacy Policy, and subscribe to email updates. Already a member: Log inBias Score Analysis
The A.I. bias rating includes policy and politician portrayal leanings based on the author’s tone found in the article using machine learning. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral.
Sentiments
43% Positive
- Liberal
| Sentence | Sentiment | Bias |
|---|---|---|
Unlock this feature by upgrading to the Pro plan. | ||
Reliability Score Analysis
Policy Leaning Analysis
Politician Portrayal Analysis
Bias Meter
Extremely
Liberal
Very
Liberal
Moderately
Liberal
Somewhat Liberal
Center
Somewhat Conservative
Moderately
Conservative
Very
Conservative
Extremely
Conservative
-100%
Liberal
100%
Conservative
Contributing sentiments towards policy:
60% : Its peers such as Roche (ROG.S), opens new tab, Eli Lilly (LLY.N), opens new tab, Johnson & Johnson (JNJ.N), opens new tab and Novartis (NOVN.S), opens new tab have also announced large-scale U.S. investments after Trump pushed for more onshore pharmaceutical manufacturing.*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization.
